Literature DB >> 3526811

Immunohistochemical study of malignant melanoma.

T Hirano.   

Abstract

Fifty-two malignant melanoma cases were divided morphologically into round, spindle and mixed-cell types and were studied immunohistochemically on the localization and staining intensity of S-100 protein and neuron specific enolase (NSE). Most of malignant melanomas were positively stained for S-100 protein and NSE. There were no correlation between the localization of S-100 protein and three cell types. However S-100 protein and degree of melanin production seemed to have an inverse relationship. On the other hand, for NSE, there were some differences on immunostaining intensity among the three cell types. Especially, deeply invasive melanomas showed strong reactivities for NSE and it may clinicopathologically indicate their poorer prognosis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3526811     DOI: 10.1111/j.1440-1827.1986.tb01060.x

Source DB:  PubMed          Journal:  Acta Pathol Jpn        ISSN: 0001-6632


  4 in total

1.  A rare case of amelanotic malignant melanoma in the oral region: Clinical investigation and immunohistochemical study.

Authors:  Yuichi Ohnishi; Masahiro Watanabe; Tomoko Fujii; Noriko Sunada; Hitoshi Yoshimoto; Hirohito Kubo; Masahiro Wato; Kenji Kakudo
Journal:  Oncol Lett       Date:  2015-10-20       Impact factor: 2.967

2.  Epithelioid cell melanomas have greater DNA ploidy abnormalities than spindle cell melanomas: cytological evidence for a higher malignant potential of the former.

Authors:  H I Chi; Y Uyeda; Y Umebayashi; F Otsuka
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

Review 3.  Neuron-specific enolase and malignant lymphomas (23 cases).

Authors:  J Nemeth; A Galian; J Mikol; B Cochand-Priollet; M Wassef; A Lavergne
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

4.  Prognosis of conjunctival melanomas in relation to histopathological features.

Authors:  U Fuchs; T Kivelä; K Liesto; A Tarkkanen
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.